Search
Diabetes Clinical Trials in Minneapolis, MN
A listing of 24 Diabetes clinical trials in Minneapolis, MN actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 12 of 24
The city of Minneapolis, Minnesota, currently has 24 active clinical trials seeking participants for Diabetes research studies.
Featured Trial
55+ Obesity and Cardiovascular Disease Clinical Study
Recruiting
Diagnosed with cardiovascular disease? Join our local overweight with cardiovascular issues clinical trial. Every 34 seconds, someone in the US dies of cardiovascular disease. Wonder how you could help? If you’re eligible for our CVD clinical trial, you could receive up to $1500.
Conditions:
Obesity
Overweight and Obesity
Cardiovascular Disease
Cardiovascular Diseases
Cardiovascular Health
Featured Trial
Type 2 Diabetes (T2DM) Trials
Recruiting
Type 2 Diabetes (T2DM) trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Type 2 Diabetes (T2DM)
Featured Trial
Cardiovascular Disease Trials
Recruiting
Cardiovascular Disease trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Cardiovascular Disease
Featured Trial
Cardiovascular Disease and Obesity Study
Recruiting
Overweight individuals diagnosed with type 2 diabetes
Featured Trial
Chronic Kidney Disease and High Blood Pressure
Recruiting
Conditions:
Kidney Disease
Chronic Kidney Disease
* Compensation for time may be available
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
Recruiting
The purpose of this study is to collect clinical data to support a 7-day wear of the Extended Wear Infusion Set (EWIS).
Participants will be asked to:
Wear the EWIS for up to 7 consecutive days for 12 consecutive wear periods
Perform blood glucose and ketone measurements if continuous glucose meter is ≥250mg/dL for one hour
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/20/2024
Locations: International Diabetes Center - HealthPartners Institute, Minneapolis, Minnesota
Conditions: Type1diabetes
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone.
Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Care Access Research - Minneapolis, Minneapolis, Minnesota
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Total Contact Soft Cast in Diabetic Foot Ulcers
Recruiting
To determine the effectiveness, compliance, patient tolerance, ease of use and safety of total contact soft cast in diabetic foot ulcers.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetic Foot Ulcer, Diabetes Mellitus, Foot Ulcer, Foot Ulcer, Diabetic, Ulcer, Ulcer Foot, Ulcer, Leg, Ankle Ulcer
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either dr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: International Diabetes Center, Minneapolis, Minnesota
Conditions: Type 2 Diabetes
Personalized Nutrition Therapy Using Continuous Glucose Monitoring to Improve Outcomes in Type 2 Diabetes Mellitus
Recruiting
Nutrition guidelines state that multiple eating patterns are effective for type 2 diabetes and that therapy should be individualized. Yet many nutrition plans fail to account for interpersonal variability in blood glucose response to meals. This diminishes the ability of dietary interventions to optimize glycemic control and may lessen patient satisfaction, self--efficacy, and adherence. Continuous glucose monitoring (CGM) can facilitate behavior change in type 2 diabetes and has been associated... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Type 2 Diabetes
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Recruiting
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: VPCI Oncology Research, Minneapolis, Minnesota
A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes
Recruiting
This study compares insulin icodec, a new insulin taken once a week, to insulin glargine, an insulin taken once a day. The study medicine will be investigated in participants with type 2 diabetes. Participants will either get insulin icodec or insulin glargine. Which treatment participants get is decided by chance. Insulin icodec is the new medicine being tested, while insulin glargine is already approved and can be prescribed by doctors. Participants will get one injection of insulin icodec onc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: International Diabetes Center, Minneapolis, Minnesota
Conditions: Diabetes, Type 2
Collaborative Solutions for Breaking up Sedentary Time in Black Older Adults With Type 2 Diabetes: The Interrupt Diabetes Study
Recruiting
The disparate burden of Type 2 Diabetes (T2D) faced by Black individuals makes attention to preventing or delaying the development of T2D and its associated cardiovascular (CV) complications, essential.
Similar to differences in cardiovascular disease (CVD) rates across racial and ethnic groups of older people, there are differences in engagement in physical activity (PA), a significant contributor to CVD. Black adults are less likely to engage in physical activity PA than their non-Hispanic Wh... Read More
Gender:
All
Ages:
55 years and above
Trial Updated:
05/24/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Cardiovascular Diseases, Type 2 Diabetes
STOP-T1D Low-Dose (ATG)
Recruiting
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.
Gender:
All
Ages:
Between 6 years and 34 years
Trial Updated:
05/24/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetes Mellitus, Type 1
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
All
Ages:
Between 12 years and 35 years
Trial Updated:
05/23/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Diabetes Mellitus, Type 1
FAM (Follower, Action Plan, and Remote Monitoring) Intervention to Reduce Severe Hyperglycemia in Adults With Type 1 Diabetes Mellitus at Risk for Diabetic Ketoacidosis
Recruiting
Diabetic ketoacidosis (DKA) results in significant morbidity and healthcare utilization and is the main contributor to loss of life expectancy in people with diabetes mellitus type 1 (T1DM) <50 years old. This suggests the need to develop interventions to reduce DKA events. Innovative features of newer continuous glucose monitoring devices offer opportunities for novel strategies to reduce DKA. Designating a family member, friend, or caregiver as a Follower was associated with reduction in HbA1C... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
05/06/2024
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Type 1 Diabetes
Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics
Recruiting
The purpose of this research study is to determine if rifampin, an antibiotic (a medicine that treats infections), is effective in treating osteomyelitis (infection of the bone) of the foot in diabetic patients. Despite use of powerful antibiotics prescribed over a long period of time, many diabetic patients remain at a high risk for needing an amputation of part of the foot or lower leg because the osteomyelitis is not cured. Some small research studies have shown that addition of rifampin to o... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
05/06/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
1 - 12 of 24